Search

Your search keyword '"Stevens-Johnson Syndrome blood"' showing total 82 results

Search Constraints

Start Over You searched for: Descriptor "Stevens-Johnson Syndrome blood" Remove constraint Descriptor: "Stevens-Johnson Syndrome blood"
82 results on '"Stevens-Johnson Syndrome blood"'

Search Results

1. Prognosis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Cohort Study of 216 Patients in an Inpatient Dermatology Department.

2. Prognostic significance of the systemic immune-inflammation index in patients with Steven-Johnson syndrome and toxic epidermal necrolysis.

3. Role of neutrophil-lymphocyte ratio as a prognostic marker in SJS/TEN patients.

4. Granulysin-Based Lymphocyte Activation Test for Evaluating Drug Causality in Antiepileptics-Induced Severe Cutaneous Adverse Reactions.

5. Carbamazepine Induces Focused T Cell Responses in Resolved Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Cases But Does Not Perturb the Immunopeptidome for T Cell Recognition.

6. Acute pancreatic injuries: A complication of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immunocell activation.

7. The Role of IL-13, IL-15 and Granulysin in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

8. Toxic epidermal necrolysis accompanied by several immune-related adverse events developed after discontinuation of nivolumab.

9. Galectin-7 as a potential biomarker of Stevens-Johnson syndrome/toxic epidermal necrolysis: identification by targeted proteomics using causative drug-exposed peripheral blood cells.

10. Successful treatment of interstitial lung disease related to Stevens-Johnson syndrome/toxic epidermal necrolysis overlap with etanercept: A case report and published work review.

11. Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients.

12. Serum and blister-fluid elevation and decreased epidermal content of high-mobility group box 1 protein in drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.

13. Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions.

14. Circulating bullous pemphigoid 180 autoantibody can be detected in a wide spectrum of patients with other dermatologic conditions: A cross-sectional study.

16. Procalcitonin as a diagnostic indicator for systemic bacterial infections in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis.

17. [Management of severe sepsis using a Cytokin-adsorber].

18. Serum IL-17 in patients with erythema multiforme or Stevens-Johnson syndrome/toxic epidermal necrolysis drug reaction, and correlation with disease severity.

19. Variable levels of apoptotic signal-associated cytokines in the disease course of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

21. Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

22. Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma.

23. A retrospective analysis of Stevens-Johnson syndrome/toxic epidermal necrolysis treated with corticosteroids.

24. The use of porcine xenografts in patients with toxic epidermal necrolysis.

25. Plasma Lipid Profiling of Patients with Chronic Ocular Complications Caused by Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

26. Development of an incipient Stevens-Johnson reaction while on a stable dose of lamotrigine.

27. Serum miR-124 up-regulation as a disease marker of toxic epidermal necrolysis.

28. Mixed signals: toxic epidermal necrolysis.

29. The serum level of HMGB1 (high mobility group box 1 protein) is preferentially high in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms.

30. Chemokine expression in diverse nonimmediate drug hypersensitivity reactions: focus on thymus activation-regulated chemokine, cutaneous T-cell-attracting chemokine, and interleukin-10.

31. Recombinant thrombomodulin improved Stevens-Johnson syndrome with high serum high-mobility group-B1 DNA-binding protein induced by lenalidomide administered to treat multiple myeloma.

32. Methylprednisolone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers.

33. Disturbed balance in three subpopulations of CD4(+)Foxp3(+) regulatory T cells in Stevens-Johnson syndrome and toxic epidermal necrolysis patients.

35. A case of toxic epidermal necrolysis with diverse etiologies: successful treatment with intravenous immunoglobulin and pulse prednisolone and effects on sTRAIL and sCD200 levels.

36. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).

37. Toxic epidermal necrolysis complicated by sepsis, haemophagocytic syndrome, and severe liver dysfunction associated with elevated interleukin-10 production.

38. Oxidative stress and leukocyte migration inhibition response in cutaneous adverse drug reactions.

39. Acute hemolysis secondary to high-dose intravenous immunoglobulin in a patient with Stevens-Johnson syndrome.

40. Evaluation of serum cytokine levels in toxic epidermal necrolysis and Stevens-Johnson syndrome compared with other delayed-type adverse drug reactions.

41. Serum bicarbonate as a marker to predict mortality in toxic epidermal necrolysis.

42. Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis.

43. Possible in vitro model of toxic epidermal necrolysis.

44. Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: Is cytokine expression analysis useful in predicting its therapeutic efficacy?

45. Differences in immunological alterations and underlying viral infections in two well-defined severe drug eruptions.

46. Ten days vs. 14 days antibiotic therapy in culture-proven neonatal sepsis.

47. [Dermatologic aspects of anticoagulation].

50. Neopterin and C-reactive protein in the course of Stevens-Johnson syndrome: report of a case.

Catalog

Books, media, physical & digital resources